{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017843","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.626565+00:00","generated_at":"2026-06-21T19:50:32.547662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Fortress Biotech reports 17.5% net revenue gain to $59.3M in 9M 2022; gets Nasdaq bid-price deficiency","bullets":["Net revenue for nine months ended Sep 30, 2022 was $59.3M, up 17.5% from the same period in 2021.","Nasdaq notified Fortress that common stock bid price closed below $1.00 for 30 consecutive business days; compliance risk.","Journey Medical, a partner, generated Q3 2022 total revenue of $16.1M, down from $19.6M in Q3 2021.","Checkpoint Therapeutics approved a 1-for-10 reverse stock split; Avenue Therapeutics completed a 1-for-15 reverse split in Sep 2022.","Board declared monthly dividends of $0.1953125 per share on Series A Preferred Stock for Oct, Nov, Dec 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017843","json":"https://secwatch.observer/filing/0001558370-22-017843.json","markdown":"https://secwatch.observer/filing/0001558370-22-017843.md","text":"https://secwatch.observer/filing/0001558370-22-017843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837022017843/0001558370-22-017843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837022017843/fbio-20221114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:50:32.547662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85ae06b30f60879d576d9e90b27fef7a4ea46391","claim":"Fortress Biotech, Inc. reported the first nine months of 2022 results: revenue $59.3 million.","evidence_excerpt":"Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000155837022017843/0001558370-22-017843-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first nine months of 2022"},{"label":"Revenue","value":"$59.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}